ID   SUSMi005-A-2.2
AC   CVCL_C0GV
SY   SNCA3X 1KO C2
DR   BioSamples; SAMEA12312966
DR   hPSCreg; SUSMi005-A-2
DR   Wikidata; Q112930438
RX   PubMed=35263701;
CC   From: Stanford University School of Medicine; Stanford; USA.
CC   Population: Caucasian.
CC   Knockout cell: Method=CRISPR/Cas9; HGNC; HGNC:11138; SNCA (Note=1 of 4 alleles).
CC   Sequence variation: Gene amplification; HGNC; HGNC:11138; SNCA; Triplication; Zygosity=Unspecified (from parent cell line).
CC   Derived from site: In situ; Skin, dermis; UBERON=UBERON_0002067.
CC   Cell type: Fibroblast of skin; CL=CL_0002620.
DI   NCIt; C198604; Parkinson disease 4, autosomal dominant
DI   ORDO; Orphanet_411602; Hereditary late-onset Parkinson disease
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_A4QV ! Trpl17
SX   Male
AG   48Y
CA   Induced pluripotent stem cell
DT   Created: 23-06-22; Last updated: 19-12-24; Version: 6
//
RX   PubMed=35263701; DOI=10.1016/j.scr.2022.102733;
RA   Zafar, Faria
RA   Nallur Srinivasaraghavan, Vasavi
RA   Chen, Max Yang
RA   Morato Torres, C. Alejandra
RA   Schule, Birgitt
RT   "Isogenic human SNCA gene dosage induced pluripotent stem cells to
RT   model Parkinson's disease.";
RL   Stem Cell Res. 60:102733-102733(2022).
//